CoChat

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 31 of the 76 sources its claims cite were checked for support.

Abstract

Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatment failure. Tumor expression of interferon (IFN) signaling, high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), and high blood interleukin-6 and ferritin levels were each associated with a lack of durable response. Similar to other cancers, we found that in LBCL tumors, IFN signaling is associated with the expression of multiple checkpoint ligands, including programmed cell death–ligand 1, and these were higher in patients who lacked durable responses to CAR-T therapy. Moreover, tumor IFN signaling and blood M-MDSCs associated with decreased axi-cel expansion. Finally, patients with high tumor burden had higher immune dysregulation with increased serum inflammatory markers and tumor IFN signaling. These data support that immune dysregulation in LBCL promotes axi-cel resistance via multiple mechanistic programs: insufficient axi-cel expansion associated with both circulating M-MDSC and tumor IFN signaling, which also gives rise to expression of immune checkpoint ligands.

Overview

CoChat Summary

TL;DR

In patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), pretherapy immune dysregulation—tumor interferon signaling, circulating monocytic myeloid-derived suppressor cells (M-MDSCs), and elevated inflammatory markers—was associated with lack of durable response. Tumor interferon signaling and M-MDSCs also associated with decreased axi-cel expansion, and high tumor burden was linked to greater systemic and tumor inflammation.

Key findings

  • Among 105 axi-cel-treated patients, lack of durable response was associated with tumor interferon signaling, high blood M-MDSCs, and high blood interleukin-6 and ferritin levels.
  • Pretreatment tumor biopsies showed higher malignant B-cell PD-L1 and MHC II in nondurable responders; RNA data showed enrichment of the tumor ISG.RS interferon signature in nondurable responders and the T-cell IFNG.GS signature in durable responders. Macrophage-associated genes CD163 (3.4-fold; P = .02) and Siglec-1 (2.9-fold; P < .001) were higher at baseline in nondurable responders.
  • Median peak axi-cel levels were 10-fold higher in durable responders than nondurable responders (P = .01); patients with high baseline M-MDSCs (greater than median; 250 cells per μL) had 4-fold lower peak axi-cel expansion (P = .02), and tumor interferon signaling genes were highly expressed in patients with poor axi-cel expansion.
  • High tumor burden (>150 mL metabolic tumor volume) was associated with higher ferritin, IL-6, IL-15, TNF-α, and ANG2/ANG1; in public NCICCR LBCL data, high ISG.RS was associated with multiple T-cell inhibitory ligands and with SOCS1 and KLHL6 mutations.

Methods

  • Observational study of samples from 105 patients treated with axi-cel: 85 received standard-of-care therapy, 14 as part of a clinical trial, and 6 under the ZUMA-9 expanded access trial. Durable responders remained in remission with a minimum follow-up of 6 months after infusion; nondurable responders died of any cause or relapsed.
  • Assays included multiplex immunofluorescence for CD19, CD20, CD3, PD-L1, MHC I, and MHC II (n = 26); NanoString IO360 gene expression (n = 35); RNA-sequencing (n = 18); flow cytometry for M-MDSCs; quantitative polymerase chain reaction for axi-cel expansion; and serum cytokine, ferritin, and CRP measurements.
  • Analyses compared durable vs nondurable responders, used gene set enrichment and GSVA for interferon signatures, assessed correlations, and interrogated the public NCICCR-DLBCL data set for ISG.RS-associated features.

Limitations

  • Paper-stated: the study was observational and therefore limited to describing associations rather than concluding causal links.
  • Paper-stated: multivariable modeling of clinical outcomes using tumor genetics, peripheral blood cytokines, metabolic tumor volume, tumor microenvironment characteristics, and circulating immune subsets would be ideal, but the authors could not analyze every biomarker in each patient because of sample-collection constraints.
  • Evident from the text: several assay-specific sample sizes were small (e.g., multiplex immunofluorescence n = 26, NanoString n = 35, RNA-sequencing n = 18, M-MDSC/TME overlap n = 11), and patients were treated across standard-of-care, clinical trial, and expanded-access settings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/blood.2020007445

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

15 Valid · 1 Not valid · 18 Not checked · 105 Own results and interpretations

78 more claims · 2 with their cited sources checked

Create a free account to see all 139 claims and to verify the 45 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 69 references

Cited by

Metadata

Authors
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., Cao, B., Chavez, J. C., Shah, B., Lazaryan, A., Nishihori, T., Hussaini, M., Gonzalez, R. J., Mullinax, J. E., Rodriguez, P. C., Conejo-Garcia, J. R., Anasetti, C., Davila, M. L., & Locke, F. L.
Affiliations
  • Department of Blood and Marrow Transplant and Cellular Immunotherapy,
  • Department of Clinical Science,
  • Department of Bioinformatics and Biostatistics,
  • Department of Malignant Hematology,
  • Department of Pathology,
  • Department of Sarcoma, and
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL
  • University of South Florida (US)
Corresponding author
  • Jain, Michael D.
  • Zhao, Hua
Venue
Blood
Published
2021-05-13
Volume
137
Issue
19
Pages
2621-2633
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3123125599
Cited by
297
References
60
Citations by year
2026: 40 · 2025: 63 · 2024: 54 · 2023: 72 · 2022: 43 · 2021: 23
FWCI
18.09
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA184185, K23CA201594, P30CA076292)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
large B-cell lymphoma, axicabtagene ciloleucel, CAR T-cell therapy, treatment failure, interferon signaling, myeloid-derived suppressor cells, immune checkpoint ligands, PD-L1, interleukin-6, ferritin, immune dysregulation, CAR-T cell expansion, tumor burden, relapsed/refractory lymphoma
MeSH terms
Myeloid-Derived Suppressor Cells, Receptors, Chimeric Antigen, Adult, Aged, Biological Products, Female, Ferritins, Humans, Interferons, Male, Middle Aged, RNA, Neoplasm, Cytokines, Immunotherapy, Adoptive, Lymphoma, B-Cell, Treatment Failure, Tumor Escape, Tumor Burden, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.